Just a recap of the acquisition...
STRATEGIC ACQUISITION OF AINSOFF PTY LTD
Today, Beamtree is also pleased to announce the acquisition of Ainsoff Pty Ltd (“Ainsoff”, a clinician-led healthcare analytics company that is bridging the gap between clinical expertise and data science. The strategic acquisition is valued at $1m through a combination of cash and shares and includes the company founders joining Beamtree, as well as three ready-for-market product applications that reduce the risk of death for seriously ill patients in hospital and automate other key clinical processes.
The three new product applications are built on the Beamtree RippleDown® platform, allowing for seamless integration into the Company’s suite of products. These products use Rippledown® decision support outside of pathology and in broader clinical practice, with one of the products recently featured in peer-reviewed journal Critical Care Medicine validating the trademarked methodology used for advanced warning of the risk of patient deterioration in hospital wards. Effective early warning of deterioration is a key clinical safety focus for hospitals around the world and especially in the context of the COVID pandemic.
The other two applications automate key clinical documentation processes in hospital and the delivery of critical diagnostic results to physicians to improve health system efficiency and financial sustainability.
Ainsoff’s founders, Dr Levi Bassin, a cardiothoracic surgeon at the Royal North Shore Hospital in Sydney, and Dr David Bell, a cardiothoracic trainee in the Royal Australasian College of Surgeons, will join Beamtree as senior technical and clinical advisors to drive implementation of these technologies in Australia and internationally.
“Ainsoff has designed world-class AI applications that have the capacity to transform the management of the most seriously ill patients in hospital and the quality and costs of clinical process in hospitals. This is a milestone for us as we look to serve the needs of health systems to continuously improve outcomes of patients,” said Kelsey. “The three products solve pain points that almost every hospital in the world has – improving safety and quality and the financial efficiency of services. In Australia alone we forecast a total addressable market of more than $200m.”
“We are clinicians who have designed services we know meet the key needs of our colleagues in Australia and around the world. We have dedicated ourselves to the urgency of putting technology to work for patients and particularly the most vulnerable,” said Dr Bassin.
“Beamtree is a well-established leader in data analytics and AI decision support and we look forward to a future in which we can play our part to support the future of medicine,” said Dr Bell.
https://www.9news.com.au/national/n...th-wales/e1b8e92f-3b7b-4171-82f9-612f316dc84c
- Forums
- ASX - By Stock
- BMT
- Ainsoff
Ainsoff, page-2
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BMT (ASX) to my watchlist
|
|||||
Last
30.5¢ |
Change
-0.005(1.61%) |
Mkt cap ! $88.15M |
Open | High | Low | Value | Volume |
31.0¢ | 31.0¢ | 30.5¢ | $79.96K | 258.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16666 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16666 | 0.300 |
1 | 41582 | 0.290 |
1 | 185000 | 0.285 |
4 | 16246 | 0.280 |
1 | 34207 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 28800 | 2 |
0.315 | 71376 | 1 |
0.320 | 71466 | 2 |
0.325 | 118476 | 3 |
0.330 | 22500 | 1 |
Last trade - 13.13pm 03/09/2024 (20 minute delay) ? |
Featured News
BMT (ASX) Chart |